Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454155 | 0.86 | NOD2 (0.37) | KMT2ASMN1; SMN2NPSR1MEN1ALDH1A1 | |
| SCHEMBL2455903 | 0.86 | NR1H2 (0.38) | KMT2ASMN1; SMN2NPSR1MEN1ALDH1A1 | |
| SCHEMBL18984611 | 0.80 | CYP4F2 (0.41) | KMT2ASMN1; SMN2NPSR1MEN1ALDH1A1 | |
| SCHEMBL18984459 | 0.80 | CYP4F2 (0.41) | KMT2ASMN1; SMN2NPSR1MEN1ALDH1A1 | |
| SCHEMBL21685651 | 0.78 | MAP4K1 (0.36) | KMT2AMEN1ALDH1A1GAANOD2 | |
| SCHEMBL21684987 | 0.77 | MAP4K1 (0.39) | KMT2ASMN1; SMN2MEN1ALDH1A1LMNA | |
| SCHEMBL4037584 | 0.77 | NOD2 (0.45) | KMT2ASMN1; SMN2MEN1NOD2NOD1 | |
| SCHEMBL18984409 | 0.76 | NOD2 (0.41) | KMT2ASMN1; SMN2NPSR1MEN1ALDH1A1 | |
| SCHEMBL18984388 | 0.76 | EP300 (0.41) | — | |
| SCHEMBL25299659 | 0.76 | NOD2 (0.37) | KMT2ASMN1; SMN2MEN1ALDH1A1NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932340-B2 | Substituted indoles | ABBVIE INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170349589-A9 | Substituted Indoles | ABBVIE INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170174688-A1 | Substituted Indoles | ABBVIE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-8202993-B2 | 5-bromo-1'-[(6-bromo-1H-indol-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8076360-B2 | e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8071622-B2 | 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2102186-B1 | INDOLES | HOFFMANN LA ROCHE (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-8026259-B2 | e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-7799923-B2 | Vasopressin receptor antagonists; (4-Benzotriazol-1-yl-piperidin-1-yl)-(5-chloro-1H-indol-2-yl)-methanone; antidepressants, anxiolytic agents; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2089381-B1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| WO-2008068185-A1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139550-A1 | INDOLES | HOFFMANN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139618-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008068183-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139554-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139548-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139549-A1 | INDOLES | HOFFMANN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008068184-A1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139552-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | KMT2A 862/4885SMN1; SMN2 3179/4885NPSR1 12/4885 |
| US-20080139548-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | KMT2A 1042/4885SMN1; SMN2 3701/4885NPSR1 30/4885 |
| US-20080139554-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | KMT2A 862/4885SMN1; SMN2 3179/4885NPSR1 12/4885 |
| US-20170174688-A1 | Substituted Indoles | SUV39H2, SUV39H1, IDO1 | KMT2A 64/4885SMN1; SMN2 1445/4885NPSR1 780/4885 |
| US-20080139550-A1 | INDOLES | HTR1A, AVPR1A, HTR4 | KMT2A 644/4885SMN1; SMN2 4289/4885NPSR1 21/4885 |
| US-20080139552-A1 | INDOLES | HTR1A, AVPR1A, HTR4 | KMT2A 634/4885SMN1; SMN2 4306/4885NPSR1 21/4885 |
| US-20080139618-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | KMT2A 1042/4885SMN1; SMN2 3701/4885NPSR1 30/4885 |
| US-20170349589-A9 | Substituted Indoles | SUV39H2, SUV39H1, IDO1 | KMT2A 64/4885SMN1; SMN2 1445/4885NPSR1 780/4885 |
| US-20080139549-A1 | INDOLES | HTR1A, AVPR1A, HTR4 | KMT2A 634/4885SMN1; SMN2 4306/4885NPSR1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.